LIFECORE BIOMEDICAL, INC. Depreciation
LIFECORE BIOMEDICAL, INC. (LFCR) reported Depreciation of $2.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. depreciation for the quarter ending 2026-06-30 was $2.52M.
- LIFECORE BIOMEDICAL, INC. depreciation for the quarter ending 2026-03-31 was $2.31M.
- LIFECORE BIOMEDICAL, INC. depreciation for the quarter ending 2025-09-30 was $1.98M.
- LIFECORE BIOMEDICAL, INC. depreciation for the quarter ending 2025-05-25 was $1.91M.
- LIFECORE BIOMEDICAL, INC. depreciation for fiscal 2025 was $8.03M, a 0.92% increase from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. depreciation for fiscal 2024 was $7.95M.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 7 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.52M 10-Q · filed 2026-08-05 | $4.83M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $2.31M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $5.54M 10-KT · filed 2026-03-16 | |||
| 2025-09-30 | $1.98M 10-Q · filed 2025-11-06 | |||
| 2025-05-25 | $1.91M 10-Q · filed 2026-08-05 | $3.99M 10-Q · filed 2026-08-05 | $8.03M 10-KT · filed 2026-03-16 | |
| 2025-02-23 | $2.08M 10-Q · filed 2026-05-06 | |||
| 2024-08-25 | $1.99M 10-Q · filed 2025-11-06 | |||
| 2024-05-26 | $7.95M 10-KT · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |